FDA Moves To Pull Breast Cancer Approval For Avastin

Law360, New York (December 16, 2010, 1:26 PM EST) -- The U.S. Food and Drug Administration has begun the process of pulling its approval of Genentech Inc.'s blockbuster cancer drug Avastin for use in breast cancer patients, announcing Thursday that the drug has not been shown to be safe and effective in treating the disease.

The FDA has informed Genentech of its plan to withdraw marketing approval of Avastin for breast cancer, but the pharmaceutical company has refused to pull the indication on the label voluntarily, according to the agency.

Genentech has 15 days to request...
To view the full article, register now.